Working… Menu
Trial record 4 of 36 for:    pharmacosmos

Intravenous Iron Isomaltoside Versus Oral Iron Supplementation for Treatment of Iron Deficiency in Pregnancy.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03188445
Recruitment Status : Recruiting
First Posted : June 15, 2017
Last Update Posted : December 18, 2018
Information provided by (Responsible Party):
Pharmacosmos A/S

Brief Summary:
Intravenous iron isomaltoside versus oral iron supplementation for treatment of iron deficiency in pregnancy

Condition or disease Intervention/treatment Phase
Iron Deficiency Anemia of Pregnancy Drug: Iron Isomaltoside 1000 Drug: ferrous fumarate with ascorbic acid Phase 4

Detailed Description:

Iron deficiency (ID) in pregnant women can cause iron deficiency anaemia (IDA). ID is defined by low iron stores, measured by a low level of s-ferritin. Iron is essential for the synthesis of haemoglobin (Hb). Anaemia is defined by a low Hb level (<11.0 g/dL in 1st trimester, <10.5 g/dL in 2nd, and <10.5 - 11.0 g/dL in 3rd trimesters).

In Danish pregnant women, who do not take iron supplementation approximately 50 % have ID and 21 % have IDA. According to WHO anaemia, defined as Hb <11.0 g/dL, regardless the cause is estimated to occur in 24 % of Danish pregnant women.

This trial is designed to evaluate and compare the effect of IV iron isomaltoside to a fixed dose of oral iron administered as tablet ferrous fumarate with ascorbic acid as correction of IDA in pregnant women after 4 weeks of standard treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Intravenous Iron Isomaltoside Versus Oral Iron Supplementation for Treatment of Iron Deficiency in Pregnancy: a Randomised, Comparative, Open-label Trial
Actual Study Start Date : July 11, 2017
Estimated Primary Completion Date : December 30, 2019
Estimated Study Completion Date : June 30, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Iron

Arm Intervention/treatment
Experimental: IV administration
Iron isomaltoside (Monofer) Administered iv
Drug: Iron Isomaltoside 1000
Administered iv

Active Comparator: Oral administration
Ferrous fumarate with ascorbic acid Administered oral
Drug: ferrous fumarate with ascorbic acid
Oral administration

Primary Outcome Measures :
  1. The primary outcome measure is the achievement of an hemoglobin equal or above 11 g/dL [ Time Frame: from baseline to 18 weeks after treatment ]

Secondary Outcome Measures :
  1. Achievement of an hemoglobin equal to or above 11 g/dL [ Time Frame: T=3 weeks, T=6 weeks, T=12 weeks, and T=18 weeks ]
  2. Change in iron biomarkers [ Time Frame: From baseline to T=3 weeks, T=6 weeks, T=12 weeks, and T=18 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:  

A subject will be eligible for inclusion in the trial if she fulfils the following criteria:

  1. Women aged ≥18 years
  2. Pregnancy at GA 14+0 - 19+0
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Women aged ≥18 years
  2. Pregnancy at GA 14+0 - 19+0
  3. Ferritin <30 μg/L after 4 weeks of standard treatment in a clinical setting
  4. Willingness to participate and attend all planned follow-up visits, and signing the in-formed consent form

Exclusion Criteria:

  1. History of anaemia caused by e.g. thalassemia, hypersplenism or haemolytic anaemia (known haematologic disorder other than iron deficiency)
  2. Iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and haemosiderosis)
  3. Drug hypersensitivity (i.e. previous hypersensitivity to IV iron)
  4. Known hypersensitivity to any excipients in the investigational drug products
  5. History of active asthma within the last 5 years
  6. History of multiple allergies
  7. Known decompensated liver cirrhosis or active hepatitis
  8. Active acute or chronic infections (assessed by clinical judgement)
  9. Rheumatoid arthritis with symptoms or signs of active inflammation
  10. Treated with IV iron products or blood transfusion within 4 weeks prior to inclusion
  11. Treated with erythropoietin (EPO) within 4 weeks prior to inclusion
  12. Participation in any other interventional trial where the trial drug has not passed 5 half-lives prior to inclusion
  13. Any other medical condition that, in the opinion of the Investigator, may cause the subject to be unsuitable for the completion of the trial or place the subject at potential risk from being in the trial
  14. Meeting RBC-transfusion criteria (Hb ≤6.9 g/dL= 4.3 mmol/L with intolerable symptoms of anaemia like severe palpitations, severe dizziness, shortness of breath at rest or syncope or an Hb ≤6.4 g/dL (4.0 mmol/L) without intolerable symptoms of anaemia)
  15. Multiple pregnancies
  16. Inability to read and understand the Danish language

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03188445

Layout table for location contacts
Contact: Lars Lykke Thomsen, MD +45 59485959

Layout table for location information
Copenhagen Recruiting
Copenhagen, Sjaeland, Denmark
Sponsors and Collaborators
Pharmacosmos A/S
Layout table for investigator information
Study Chair: Lars Lykke Thomsen, MD Pharmacosmos A/S

Layout table for additonal information
Responsible Party: Pharmacosmos A/S Identifier: NCT03188445     History of Changes
Other Study ID Numbers: P-Monofer-PREG-01
First Posted: June 15, 2017    Key Record Dates
Last Update Posted: December 18, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Iron-Deficiency
Anemia, Hypochromic
Hematologic Diseases
Iron Metabolism Disorders
Metabolic Diseases
Ferrous fumarate
Ascorbic Acid
Iron isomaltoside 1000
Trace Elements
Growth Substances
Physiological Effects of Drugs
Molecular Mechanisms of Pharmacological Action
Protective Agents